Unlocking Asthma Relief: The AIRLYMPUS Study's Quest for Better Breathing Solutions

The AIRLYMPUS Study is investigating a new drug for adults with asthma to see if it can improve breathing, alleviate symptoms, and reduce future attacks when added to standard therapy. Eligible participants are aged 18-80, have had asthma for at least a year, and are on daily treatment.

The BLU-808-1201 study is seeking participants with chronic spontaneous urticaria who still experience symptoms despite antihistamine use. This study involves an oral tablet, lab tests, and monitoring, with reimbursement for expenses.

A Phase 2b trial for EVO756, an investigational therapy for atopic dermatitis, is enrolling adults. This study targets MRGPRX2, a key itch and inflammation driver, offering a potential new path for eczema relief.

Asthma can be dormant for years but may return due to various factors. It's crucial to manage asthma with prescribed medications and avoid triggers.

The Atopic Dermatitis in America study by AAFA and NEA highlights that 7.3% of U.S. adults have AD, with 40% experiencing moderate to severe symptoms. The study aims to understand the prevalence, severity, and burden of AD.

Lucid Health Solutions Embedding the patient, caregiver and provider perspective into every decision that shapes health outcomes https://www.lucidhealthsolutions.com

Lucid Health Solutions Embedding the patient, caregiver and provider perspective into every decision that shapes health outcomes https://www.lucidhealthsolutions.com

What is NextGen Patient Voice?

NextGen Patient Voice explores how research, AI, and public policy are transforming patient advocacy. Each episode breaks down the ideas, tools, and decisions shaping the future of healthcare, with a focus on what they mean for patients, caregivers, and advocates. Clear, practical, and forward-looking, this podcast connects innovation to real-world patient impact.